Clinical Trials
4
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Klus Pharma Inc.
- Target Recruit Count
- 498
- Registration Number
- NCT05816252
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Chongqing University Cancer Hospital (Chongqing Cancer Hospital), Chongqing, Chongqing, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
- First Posted Date
- 2022-12-08
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Klus Pharma Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT05642780
- Locations
- 🇺🇸
Community Clinical Research Center, Anderson, Indiana, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
🇺🇸Anne Arundel Medical Center (AAMC), Annapolis, Maryland, United States
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
- Conditions
- Epithelial Ovarian CancerGastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaUrothelial CarcinomaSmall-Cell Lung CancerEndometrial CarcinomaHead and Neck Squamous Cell CarcinomaBreast CancerCervical CancerNon-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Klus Pharma Inc.
- Target Recruit Count
- 1410
- Registration Number
- NCT04152499
- Locations
- 🇺🇸
Los Angeles Hematology Oncology Medical Group, Glendale, California, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
🇺🇸Florida Cancer Specialists and Research Institute, Sarasota, Florida, United States
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
- Conditions
- HER-2 Gene AmplificationSalivary Gland TumorLung CancerRare DiseasesHead and Neck CancerBile Duct CancerProstate CancerRecurrent Prostate CancerRectal CancerRectal Cancer Stage III
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Klus Pharma Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT03602079
- Locations
- 🇺🇸
Florida Cancer Specialists & Research Institute, Sarasota, Florida, United States
🇺🇸Beth Israel Deaconess Medical Center Cancer Center, Boston, Massachusetts, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
News
Kelun-Biotech Raises $250 Million in Largest Hong Kong Biopharma Follow-On Offering in 12 Months
Kelun-Biotech successfully completed a $250 million share placement on June 5, 2025, representing the largest follow-on offering in Hong Kong's biopharma sector over the past 12 months.
Kelun-Biotech's SKB445 ADC Receives NMPA Approval for Advanced Solid Tumor Trials
Kelun-Biotech's SKB445, a novel antibody-drug conjugate (ADC), has been approved by China's NMPA for clinical trials in advanced solid tumors.